A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2016
At a glance
- Drugs MS 553 (Primary)
- Indications Diabetic retinopathy
- Focus Adverse reactions
- Sponsors MingSight Pharmaceuticals
- 14 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 10 Jun 2015 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
- 07 Apr 2015 New trial record